| アブストラクト | Conventional vaccines have been widely studied, along with their risk of causing allergic reactions. These generally consist of mild local reactions and only rarely severe anaphylaxis. Although all the current COVID-19 vaccines marketed in Europe have been shown to be safe overall in the general population, early post-marketing evidence has shown that mRNA-based vaccines using novel platforms (i.e., lipid nanoparticles) were associated with an increased risk of severe allergic reactions as compared to conventional vaccines. In this paper we performed an updated literature review on frequency, risk factors, and underlying mechanisms of COVID-19 vaccine-related allergies by searching MEDLINE and Google Scholar databases. We also conducted a qualitative search on VigiBase and EudraVigilance databases to identify reports of "Hypersensitivity" and "Anaphylactic reaction" potentially related to COVID-19 vaccines (Comirnaty, Spikevax, Vaxzevria and COVID-19 Janssen Vaccine), and in EudraVigilance to estimate the reporting rates of "Anaphylactic reaction" and "Anaphylactic shock" after COVID-19 vaccination in the European population. We also summarized the scientific societies' and regulatory agencies' recommendations for prevention and management of COVID-19 vaccine-related allergic reactions, especially in those with a history of allergy. |
|---|
| ジャーナル名 | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy |
|---|
| Pubmed追加日 | 2022/6/14 |
|---|
| 投稿者 | Luxi, Nicoletta; Giovanazzi, Alexia; Arcolaci, Alessandra; Bonadonna, Patrizia; Crivellaro, Maria Angiola; Cutroneo, Paola Maria; Ferrajolo, Carmen; Furci, Fabiana; Guidolin, Lucia; Moretti, Ugo; Olivieri, Elisa; Petrelli, Giuliana; Zanoni, Giovanna; Senna, Gianenrico; Trifiro, Gianluca |
|---|
| 組織名 | Department of Diagnostics and Public Health, Section of Pharmacology, University;of Verona, Verona, Italy.;Immunology Unit, University Hospital, Azienda Ospedaliera Universitaria;Integrata, Verona, Italy.;Asthma Centre and Allergy Unit, University of Verona and Verona University;Hospital, Verona, Italy.;Department of Cardiac-Thoracic-Vascular Sciences and Public Health, University of;Padua, Padua, Italy.;Sicilian Regional Pharmacovigilance Centre, University Hospital of Messina,;Messina, Italy.;Department of Experimental Medicine, Section of Pharmacology "L. Donatelli",;Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology,;University of Campania "Luigi Vanvitelli", Naples, Italy.;of Verona, Verona, Italy. gianluca.trifiro@univr.it. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35696066/ |
|---|
